Philogen (PHIL) 주식 개요
생명공학 회사인 Philogen S.p.A.는 종양학 및 만성 염증성 질환 치료제를 개발하는 회사입니다. 자세히 보기
PHIL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharmaceuticals & Biotech opportunity
Philogen S.p.A. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | €21.30 |
| 52주 최고가 | €27.80 |
| 52주 최저가 | €19.56 |
| 베타 | -0.017 |
| 1개월 변동 | 3.90% |
| 3개월 변동 | 0.47% |
| 1년 변동 | -2.29% |
| 3년 변동 | 42.00% |
| 5년 변동 | 44.90% |
| IPO 이후 변동 | 27.62% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Apr 20
PHIL: Softer Earnings Outlook And 2026 Board Milestones Will Shape Repricing Potential
Analysts have reduced their price target on Philogen from €26 to €23. They point to softer revenue growth expectations, a lower projected profit margin and a higher future P/E multiple as key drivers of the revision.
새 내러티브 • Apr 09
Clinical Pipeline And Radiopharmaceutical Expansion Will Pressure Margins And Future Earnings Potential
Catalysts About Philogen Philogen develops targeted biological and small molecule therapies, primarily for oncology and certain inflammatory diseases. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Apr 06
PHIL: 2026 Board Calendar And Steady Assumptions Will Support Future Repricing Potential
Analysts have kept their fair value estimate for Philogen steady at €26.0 per share, citing largely unchanged assumptions on the discount rate, revenue trends, profit margin and future P/E as reasons for maintaining their price target. What's in the News Board meeting scheduled for March 27, 2026, to approve the Draft Financial Statements and the 2025 Consolidated Financial Statements (company filing) Board meeting set for May 12, 2026, to approve a press release containing a quarterly report with selected information on business performance for the first quarter of 2026 (company filing) Board meeting planned for September 23, 2026, to approve the Half-Yearly Financial Report as at June 30, 2026 (company filing) Board meeting scheduled for November 12, 2026, to approve a press release with a quarterly report providing selected information on business performance for the third quarter of 2026 (company filing) Valuation Changes Fair Value: unchanged at €26.0 per share, with no adjustment to the overall fair value estimate.Recent updates
내러티브 업데이트 • Apr 20
PHIL: Softer Earnings Outlook And 2026 Board Milestones Will Shape Repricing Potential
Analysts have reduced their price target on Philogen from €26 to €23. They point to softer revenue growth expectations, a lower projected profit margin and a higher future P/E multiple as key drivers of the revision.새 내러티브 • Apr 09
Clinical Pipeline And Radiopharmaceutical Expansion Will Pressure Margins And Future Earnings Potential
Catalysts About Philogen Philogen develops targeted biological and small molecule therapies, primarily for oncology and certain inflammatory diseases. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Apr 06
PHIL: 2026 Board Calendar And Steady Assumptions Will Support Future Repricing Potential
Analysts have kept their fair value estimate for Philogen steady at €26.0 per share, citing largely unchanged assumptions on the discount rate, revenue trends, profit margin and future P/E as reasons for maintaining their price target. What's in the News Board meeting scheduled for March 27, 2026, to approve the Draft Financial Statements and the 2025 Consolidated Financial Statements (company filing) Board meeting set for May 12, 2026, to approve a press release containing a quarterly report with selected information on business performance for the first quarter of 2026 (company filing) Board meeting planned for September 23, 2026, to approve the Half-Yearly Financial Report as at June 30, 2026 (company filing) Board meeting scheduled for November 12, 2026, to approve a press release with a quarterly report providing selected information on business performance for the third quarter of 2026 (company filing) Valuation Changes Fair Value: unchanged at €26.0 per share, with no adjustment to the overall fair value estimate.내러티브 업데이트 • Mar 23
PHIL: 2026 Board Schedule Will Support Confidence In Future Repricing Potential
Analysts have kept their price target for Philogen steady at €26.0, indicating only minimal tweaks in the discount rate and forward P/E assumptions, while leaving profit margin expectations unchanged. What's in the News Board meeting scheduled for March 27, 2026, to approve the Draft Financial Statements and the 2025 Consolidated Financial Statements (company event) Board meeting set for May 12, 2026, to approve a press release containing a quarterly report with selected information on the first quarter of 2026 (company event) Board meeting planned for September 23, 2026, to approve the Half-Yearly Financial Report as at June 30, 2026 (company event) Board meeting scheduled for November 12, 2026, to approve a press release containing a quarterly report with selected information on the third quarter of 2026 (company event) Valuation Changes Fair Value: kept steady at €26.0 per share, with no change in the central valuation level.내러티브 업데이트 • Mar 08
PHIL: 2026 Board Timetable Will Support Confidence In Future Upside
Analysts have left their fair value estimate for Philogen steady at €26.0. They point to only minor tweaks in the discount rate and assumed future P/E that reflect updated risk and earnings assumptions rather than a shift in their overall view. What's in the News Board meeting scheduled for March 27, 2026 to approve the Draft Financial Statements and the 2025 Consolidated Financial Statements (company filing) Board meeting set for May 12, 2026 to approve the press release that will contain the quarterly report with selected information on first quarter 2026 performance (company filing) Board meeting planned for September 23, 2026 to approve the Half-Yearly Financial Report as at June 30, 2026 (company filing) Board meeting on November 12, 2026 to approve the press release that will contain the quarterly report with selected information on third quarter 2026 performance (company filing) Valuation Changes Fair Value: Kept steady at €26.0 per share, with no change in the headline estimate.내러티브 업데이트 • Feb 21
PHIL: 2026 Board Milestones Will Support Confidence In Future Upside
Analysts have made only a marginal adjustment to their valuation framework for Philogen, keeping the fair value anchor steady at around €26 while fine tuning inputs such as the discount rate, revenue growth assumptions and future P/E to reflect updated risk and earnings expectations. What's in the News Board meeting scheduled for March 27, 2026, to approve the draft financial statements and the 2025 consolidated financial statements (company event calendar).내러티브 업데이트 • Feb 06
PHIL: Upcoming Trial Readouts And 2026 Milestones Will Support Upside Potential
Narrative Update on Philogen Analysts now set their price target for Philogen at €26.00, broadly in line with the prior €26 level. This reflects modestly lower discount rate and future P/E assumptions that fine tune their view of the company’s risk and valuation profile.내러티브 업데이트 • Jan 23
PHIL: Future Sarcoma Trial Data Will Support Upside Potential
Analysts have modestly lifted their price target for Philogen to €26.00 per share, reflecting small tweaks to their discount rate and long term P/E assumptions, while keeping fair value otherwise unchanged. What's in the News Philogen provided an update on the FIBROSARC Phase III trial, which tests fibromun plus doxorubicin versus doxorubicin alone as first line treatment for advanced or metastatic soft tissue sarcoma.내러티브 업데이트 • Jan 08
PHIL: Future Sarcoma Trial Data Will Support Upside Potential
Analysts have adjusted their price target for Philogen to €26.00. The change reflects slightly higher perceived risk through a modestly higher discount rate and a broadly unchanged outlook for margins and future P/E assumptions.내러티브 업데이트 • Dec 19
PHIL: Future Sarcoma Trial Progress Will Support Upside From Current Levels
Analysts have nudged their price target on Philogen slightly higher to €26.00. This reflects unchanged assumptions on fair value, discount rate, and long term profitability, while acknowledging the resilience of the company’s margin outlook despite subdued growth expectations.내러티브 업데이트 • Dec 05
PHIL: Future Trial Milestones And Buyback Activity Will Support Fair Value
Analysts have modestly raised their price target on Philogen to €26.00 per share, reflecting improved expectations for long term profit margins and valuation multiples, despite slightly lower near term revenue growth forecasts. What's in the News Philogen reported updated data from its FIBROSARC Phase III trial of fibromun plus doxorubicin in advanced or metastatic soft tissue sarcoma, with primary endpoint progression free survival and plans to present full results at scientific conferences and in a peer reviewed journal in 2026 (Key Developments).내러티브 업데이트 • Nov 20
PHIL: Share Buyback and Stable Financials Will Support Current Fair Value
Narrative Update on Philogen Analysts have maintained their price target for Philogen at €26.00. They cite continued confidence in the company’s outlook despite only minor adjustments to valuation inputs.내러티브 업데이트 • Nov 05
PHIL: Share Buyback and Stable Metrics Expected to Sustain Fair Value
Narrative Update: Philogen Price Target Revision Analysts have maintained Philogen's fair value estimate at €26.00. Adjustments in future revenue growth and profit margin expectations are key supporting factors for this unchanged target.내러티브 업데이트 • Oct 22
Analysts Maintain €26 Target for Philogen as Buyback and Valuations Remain Stable
Analysts have maintained their price target for Philogen at €26.00 per share, citing stable expectations for key financial metrics and future performance. What's in the News Philogen completed the repurchase of 29,448 shares, representing 0.07% of total shares, for €0.66 million under the buyback program announced on May 12, 2025 (Key Developments).내러티브 업데이트 • Oct 08
Late-stage Approvals Plus Sun Pharma Will Transform Oncology Despite Risks
Analysts have lowered their price target for Philogen from $28.00 to $26.00. This decision is based on revisions in revenue growth projections and a significant reduction in estimated profit margins.분석 기사 • Oct 04
Philogen's (BIT:PHIL) Earnings Aren't As Good As They Appear
Despite posting strong earnings, Philogen S.p.A.'s ( BIT:PHIL ) stock didn't move much over the last week. We decided...새 내러티브 • Aug 20
Late-stage Approvals Plus Sun Pharma Will Transform Oncology Despite Risks
Key Takeaways Advancing late-stage therapies and strategic pharma partnerships position Philogen for recurring product sales, stronger margins, and reduced funding risk through enhanced cash flow visibility. Alignment with personalized medicine trends and a robust cash position support long-term growth, innovation, and protection of shareholder value amid rising global demand for oncology solutions.분석 기사 • Apr 14
Analyst Forecasts For Philogen S.p.A. (BIT:PHIL) Are Surging Higher
Philogen S.p.A. ( BIT:PHIL ) shareholders will have a reason to smile today, with the analysts making substantial...분석 기사 • Mar 31
Earnings Update: Philogen S.p.A. (BIT:PHIL) Just Reported And Analysts Are Boosting Their Estimates
Philogen S.p.A. ( BIT:PHIL ) last week reported its latest yearly results, which makes it a good time for investors to...분석 기사 • Feb 24
What Philogen S.p.A.'s (BIT:PHIL) P/S Is Not Telling You
You may think that with a price-to-sales (or "P/S") ratio of 25.1x Philogen S.p.A. ( BIT:PHIL ) is a stock to avoid...분석 기사 • Jun 03
Here's Why We're Watching Philogen's (BIT:PHIL) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...주주 수익률
| PHIL | IT Biotechs | IT 시장 | |
|---|---|---|---|
| 7D | -1.6% | 0.8% | 1.6% |
| 1Y | -2.3% | 32.3% | 20.1% |
수익률 대 산업: PHIL은 지난 1년 동안 32.3%의 수익을 기록한 Italian Biotechs 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: PHIL은 지난 1년 동안 20.1%를 기록한 Italian 시장보다 저조한 성과를 냈습니다.
주가 변동성
| PHIL volatility | |
|---|---|
| PHIL Average Weekly Movement | 4.0% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IT Market | 8.1% |
| 10% least volatile stocks in IT Market | 3.0% |
안정적인 주가: PHIL는 지난 3개월 동안 Italian 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: PHIL의 주간 변동성(4%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1996 | 214 | Dario Neri | www.philogen.com |
생명공학 기업인 필로젠은 종양학 및 만성 염증성 질환 치료제를 개발하는 회사입니다. 국소 흑색종 및 비흑색종 피부암을 치료하기 위해 개발된 면역 사이토카인 L19IL2와 L19TNF의 조합으로 국소 흑색종 및 비흑색종 치료제로 개발 중인 니들리, 연조직 육종, 평활근육종, 신경교종 치료를 위해 L19 항체와 TNF로 구성된 인간 면역 조절 제품인 파이브로문(Fibromun)을 개발 중입니다; 그리고 비소세포폐암 치료를 위한 임상 2상 시험 중인 인간 사이토카인 인터루킨-2(IL2)에 인간 L19 항체를 융합한 인간 면역조절 제품인 달루킨(L19IL2)을 개발 중입니다. 또한 진행성 고형암 치료를 위해 임상 1상/2상 중인 인터루킨-12에 융합된 혈관 표적 항체로 구성된 인간 면역증강제 도데킨과 만성 염증성 질환 치료를 위해 임상 2상 중인 항염증제 데카빌(F8IL10)을 개발 중입니다; 임상 1상 중인 고형암 표면에 발현되는 탄산탈수효소 IX(CAIX)의 비침습적 검출을 위한 99mTc 표지 소분자 방사성동위원소 Onco IX(PHC-102), 임상 1상 중인 섬유아세포 활성화 단백질을 표적으로 하는 다양한 전이성 고형암 비침습적 검출용 소분자 방사성동위원소 OncoFAP를 개발 중이다.
Philogen S.p.A. 기초 지표 요약
| PHIL 기초 통계 | |
|---|---|
| 시가총액 | €874.10m |
| 순이익 (TTM) | €229.68m |
| 매출 (TTM) | €319.73m |
3.7x
주가수익비율(P/E)2.7x
주가매출비율(P/S)PHIL는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| PHIL 손익계산서 (TTM) | |
|---|---|
| 매출 | €319.73m |
| 매출원가 | €39.57m |
| 총이익 | €280.16m |
| 기타 비용 | €50.49m |
| 순이익 | €229.68m |
최근 보고된 실적
Dec 31, 2025
다음 실적 발표일
May 12, 2026
| 주당순이익(EPS) | 5.70 |
| 총이익률 | 87.62% |
| 순이익률 | 71.83% |
| 부채/자본 비율 | 0.01% |
PHIL의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기배당
3.3%
현재 배당 수익률12%
배당 성향기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/08 17:30 |
| 종가 | 2026/05/08 00:00 |
| 수익 | 2025/12/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Philogen S.p.A.는 4명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Rajan Sharma | Goldman Sachs |
| Victor Floch | Stifel, Equities Research |
| Clemence Thiers | Stifel, Equities Research |